[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340564-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340564-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mimicking-retinoblastoma-treatment-with-repeated-topotecan-or-melphalan-develops-cross-resistance-to-classic-agents-but-not-to-repurposed-drugs","Mimicking Retinoblastoma Treatment With Repeated Topotecan or Melphalan Develops Cross-Resistance to Classic Agents But Not to Repurposed Drugs","","Refractory or recurrent retinoblastoma commonly reflects acquired chemoresistance, often requiring surgical removal. This study creates in vitro retinoblastoma models by repeatedly exposing primary cancer cell cultures to weekly melphalan or topotecan, mimicking clinical treatment exposure. Chemoresistant lines show elevated IC50 values for the matched classic agents and cross-resistance between melphalan and topotecan. Resistance also reduces carboplatin sensitivity, while repurposed agents remain unaffected; transporter expression shifts are observed, supporting further therapeutic development.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mimicking-retinoblastoma-treatment-with-repeated-topotecan-or-melphalan-develops-cross-resistance-to-classic-agents-but-not-to-repurposed-drugs/340564/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mimicking-retinoblastoma-treatment-with-repeated-topotecan-or-melphalan-develops-cross-resistance-to-classic-agents-but-not-to-repurposed-drugs/340564.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main objective?","Question",{"text":63,"@type":64},"To develop retinoblastoma models resistant to chemotherapy by exposing cancer cells to repeated treatment that mimics the clinical scenario, enabling evaluation of potential novel therapies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were chemoresistant retinoblastoma cell models generated?",{"text":68,"@type":64},"Two primary retinoblastoma cell cultures were exposed to three weekly doses of melphalan or topotecan, and then their drug sensitivity was measured.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about cross-resistance and repurposed drugs?",{"text":72,"@type":64},"Chemoresistant cells developed cross-resistance between melphalan and topotecan and showed reduced sensitivity to carboplatin, while sensitivity to the evaluated repurposed agents (digoxin, methylene blue, and gemcitabine) remained unchanged.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340564,1790360462,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Anatomy and Pathology/Oncology  \nMimicking Retinoblastoma Treatment With Repeated Topotecan or Melphalan Develops Cross-Resistance to Classic Agents But Not to Repurposed Drugs  \nMaría Belen Cancela,1 ,2 Ursula Winter,2 Santiago Zugbi,1 ,2 Milagros Dinardi,1 Daniela Alves da Quinta,2 ,3 Rosario Aschero,4 ,5 Daiana Ganiewich,3 Claudia Sampor,6 Mariana Sgroi,7 Eduardo Lagomarsino,8 Adriana Fandiño,7 Andrea S. Llera,2 ,3 Guillermo Chantada,4 ,5 Angel M. Carcaboso,4 ,5 and Paula Schaiquevich1 ,2  \n1Unit of Innovative Treatments, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina  \n2National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina  \n3Laboratory of Molecular and Cellular Therapy, Instituto Leloir – Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina  \n4 SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain  \n5 Institut de Recerca Sant Joan de Deu, Barcelona, Spain  \n6Hematology-Oncology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina  \n7 Ophthalmology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina  \n8Pharmacy Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina  \nCorrespondence: Paula Schaiquevich, Combate de los pozos 1881, CP1245, CABA, Buenos Aires, Argentina;  \n[paulas@conicet.gov.ar](paulas@conicet.gov.ar).  \nAngel M. Carcaboso, SJD Pediatric Cancer Center Barcelona, Santa Rosa 39-57, 08950 Esplugues de Llobregat, Barcelona 08950, Spain; [angel.montero@sjd.es](angel.montero@sjd.es).  \nAMC and PS jointly supervised this work.  \nReceived: October 10, 2024  \nAccepted: November 8, 2024  \nPublished: December 5, 2024  \nCitation: Cancela MB, Winter U, Zugbi S, et al. Mimicking retinoblastoma treatment with repeated topotecan or melphalan develops cross-resistance to classic agents but not to repurposed drugs. Invest Ophthalmol Vis Sci. 2024;65(14):14 .  \n[https://doi.org/10.1167/iovs.65.14.14](https://doi.org/10.1167/iovs.65.14.14)  \nPURPOSE. Refractory or recurrent retinoblastoma results from acquired chemoresistance and the management of these eyes often requires surgical removal. Our objective was to develop retinoblastoma models resistant to chemotherapy by exposing cancer cells to repeated chemotherapy mimicking the clinical scenario. These newly resistant cells were used to evaluate potential novel therapies.  \nMETHODS. Chemoresistant cells were obtained by exposing two primary retinoblastoma cell cultures to three weekly doses of melphalan or topotecan. The sensitivity of these resistant cells to each chemotherapy was evaluated, and cross-resistance to topotecan, melphalan, and carboplatin was assessed. Genomic alterations and differential expression of efflux/influx transporters between chemoresistant and parental cells were analyzed. Subsequently, sensitivity of both resistant and parental cells to the repurposed agents digoxin, methylene blue, and gemcitabine was assessed.  \nRESULTS. Four chemoresistant models were successfully established, showing significantly higher half-maximal inhibitory concentration (IC50) values for melphalan and topotecan compared to their corresponding parental cells (P \u003C 0.05) . Cross-resistance between melphalan and topotecan was demonstrated, with a 3-fold increase in the IC50 . Chemoresistant cells also showed reduced sensitivity to carboplatin (P \u003C 0.05) compared to parental cells, whereas sensitivity to the evaluated repurposed agents remained unchanged. Genomic analysis revealed no selective alterations in the resistant cells, although differential expression of influx/efflux transporters was observed across all chemoresistant models.  \nCONCLUSIONS. In vitro simulation of patient treatment was useful to establish chemoresistant retinoblastomas and to identify strategies to overcome resistance totopotecan or melphalan through drug repurposed. Our results warrant further investigation to support the clinical translation.  \nKeywor","cbCaiibxIeltv3Cx","https://ap.wps.com/l/cbCaiibxIeltv3Cx","pdf",1768118,12,"English","# Purpose\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What was the study’s main objective?\",\"answer\":\"To develop retinoblastoma models resistant to chemotherapy by exposing cancer cells to repeated treatment that mimics the clinical scenario, enabling evaluation of potential novel therapies.\"},{\"question\":\"How were chemoresistant retinoblastoma cell models generated?\",\"answer\":\"Two primary retinoblastoma cell cultures were exposed to three weekly doses of melphalan or topotecan, and then their drug sensitivity was measured.\"},{\"question\":\"What did the results show about cross-resistance and repurposed drugs?\",\"answer\":\"Chemoresistant cells developed cross-resistance between melphalan and topotecan and showed reduced sensitivity to carboplatin, while sensitivity to the evaluated repurposed agents (digoxin, methylene blue, and gemcitabine) remained unchanged.\"}]","Mimicking Retinoblastoma Treatment With Repeated Topotecan or Melphalan Develops Cross-Resistance to Classic Agents But Not to Repurposed Drugs | PDF",1790037342,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0762dee1011a18333dda29491ea7e190.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcf173847729248d38da482c4081eef8.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f12ee8325bcfd5d236b5fda51fef6ee.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/540193b25ce648e1aad9cb73e74fe6d8.webp",980,1268]